Larimar Therapeutics (NASDAQ:LRMR) Reaches New 1-Year High Following Analyst Upgrade

Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) hit a new 52-week high during trading on Wednesday after Citigroup raised their price target on the stock from $12.00 to $14.00. Citigroup currently has a buy rating on the stock. Larimar Therapeutics traded as high as $6.42 and last traded at $6.00, with a volume of 63963993 shares traded. The stock had previously closed at $3.69.

LRMR has been the subject of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, January 22nd. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Larimar Therapeutics in a research report on Wednesday. Lifesci Capital upgraded Larimar Therapeutics to a “strong-buy” rating in a research note on Tuesday. Finally, Leerink Partners raised Larimar Therapeutics to a “strong-buy” rating in a research report on Monday, January 5th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Larimar Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $16.14.

More Larimar Therapeutics News

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, management reiterated a planned BLA submission in June 2026 and target U.S. launch in H1 2027 if approved — a development that materially de-risks the program and supports accelerated approval prospects. Article Title
• Positive Sentiment: Several analysts upgraded or raised price targets (Citigroup to $14 buy, Wedbush reaffirmed outperform with $11 PT, Lifesci Capital to strong-buy), signaling institutional bullishness that can support upside momentum. Article Title
• Neutral Sentiment: Unusual options activity: traders bought ~3,744 calls (≈456% above typical daily call volume), indicating speculative/leveraged bullish positioning that may amplify intraday moves but is not a fundamental change.
• Neutral Sentiment: Media coverage and headlines about the FDA action drove a sharp pre-market surge and massive intraday trading volume (recent reports show daily volume far above the stock’s average), increasing volatility and short-term liquidity. Article Title
• Negative Sentiment: Larimar filed a proposed underwritten public offering of $75 million of common stock (with an underwriter option for an additional $11.25M) — a sizable raise relative to its market cap that introduces near-term dilution risk and can pressure the share price until proceeds are deployed. The offering is subject to market conditions and may create volatility. Article Title

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in LRMR. AQR Capital Management LLC purchased a new stake in Larimar Therapeutics in the first quarter valued at about $241,000. Acadian Asset Management LLC purchased a new stake in shares of Larimar Therapeutics during the first quarter worth about $113,000. Rhumbline Advisers increased its holdings in shares of Larimar Therapeutics by 15.7% during the first quarter. Rhumbline Advisers now owns 65,018 shares of the company’s stock valued at $140,000 after acquiring an additional 8,818 shares in the last quarter. CWM LLC increased its holdings in shares of Larimar Therapeutics by 205.0% during the second quarter. CWM LLC now owns 32,652 shares of the company’s stock valued at $94,000 after acquiring an additional 21,948 shares in the last quarter. Finally, Ethic Inc. purchased a new position in shares of Larimar Therapeutics in the 2nd quarter valued at approximately $187,000. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

Larimar Therapeutics Stock Performance

The business’s 50 day moving average is $3.49 and its 200 day moving average is $3.77. The company has a market capitalization of $492.54 million, a price-to-earnings ratio of -3.08 and a beta of 1.00.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.